Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

BUY
$17.4 - $94.5 $626,400 - $3.4 Million
36,000 New
36,000 $2.95 Million
Q2 2023

Aug 14, 2023

BUY
$14.84 - $24.79 $1.21 Million - $2.02 Million
81,500 New
81,500 $1.32 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.83B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Nomura Holdings Inc Portfolio

Follow Nomura Holdings Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Holdings Inc with notifications on news.